8-K: XWELL Inc. Reports Fiscal Year 2023 Results, Highlights Growth and Cost Reductions

XWELL, Inc. announced its 2023 financial results, showcasing revenue growth in its XpresSpa segment and significant cost reductions, while also expanding its biosurveillance program and out-of-airport presence.

Summary

• XWELL, Inc. reported its financial results for the fiscal year ended December 31, 2023.
• The company's XpresSpa business segment saw a revenue increase of approximately 39% compared to 2022.
• XWELL opened its 11th international XpresSpa location in Abu Dhabi International Airport.
• The company is expanding beyond airports, including a new XpresSpa in Penn Station, New York City, and multiple new Naples Wax Center locations in Florida.
• XWELL and Ginkgo Bioworks expanded their CDC Traveler-based Genomic Surveillance Program to new airports in Miami and Chicago.
• The company reduced costs by approximately $11 million through headcount, systems, and process reductions.
• Total cost of sales decreased by approximately 40% and salaries, general, and administrative expenses decreased by approximately 33% compared to 2022.
• XWELL reported an operating loss of approximately $28.2 million for 2023, an improvement from the $31.2 million loss in 2022.
• Total revenue for 2023 was $30.1 million, down from $55.9 million in the prior year.
• The company had approximately $8.4 million in cash and cash equivalents and $14.6 million in marketable securities as of December 31, 2023, with no long-term debt.

Sentiment

Score: 5

Explanation: The document presents a mixed picture with positive growth in some areas and significant cost reductions, but also a substantial revenue decline, a net loss, and a restatement of financials. The sentiment is neutral to slightly negative due to the financial losses and accounting issues.

Positives

• The XpresSpa segment experienced significant revenue growth of approximately 39% year-over-year.
• The company successfully reduced its cost structure, leading to a 40% decrease in total cost of sales and a 33% decrease in salary, general, and administrative expenses.
• XWELL is expanding its reach beyond airports with new locations in Penn Station and multiple Naples Wax Center locations.
• The company's biosurveillance program with the CDC and Ginkgo Bioworks continues to expand, with new locations and increased funding.
• The operating loss decreased from $31.2 million in 2022 to $28.2 million in 2023, indicating progress towards profitability.
• XWELL has a strong liquidity position with $8.4 million in cash and cash equivalents and $14.6 million in marketable securities and no long-term debt.

Negatives

• Total revenue decreased from $55.9 million in 2022 to $30.1 million in 2023.
• The company reported a net loss of approximately $28.0 million for 2023.
• Non-cash goodwill and intangible asset impairment charges totaled approximately $8.9 million.
• The company restated its Q3 2023 financial statements due to an error in the impairment calculation for the Treat business segment, resulting in an understatement of $1.6 million.
• Unaudited financial statements for Q3 2023 should no longer be relied upon.

Risks

• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• The company's ability to achieve profitability in 2024 is dependent on continued cost reductions and revenue growth.
• The restatement of Q3 2023 financials may raise concerns about the company's accounting practices.
• The company's expansion plans may face challenges in execution and market acceptance.
• The biosurveillance program is subject to government funding and may be impacted by changes in priorities.

Future Outlook

XWELL remains focused on improving operating performance, reaching profitability, and delivering long-term strategic priorities, including expanding its wellness portfolio and opening new locations for XpresSpa and Naples Wax Center.

Management Comments

• Scott Milford, XWELL's Chief Executive Officer, stated that the company is diligently executing its strategy to drive revenue growth and return to profitability.
• Mr. Milford highlighted the company's international growth, cost-effective integration of wellness services, expansion of the biosurveillance partnership, and expansion outside of airports.
• Mr. Milford noted the company's focus on driving retail revenue growth and leveraging its brands beyond traditional venues.
• Mr. Milford stated that the company remains focused on expanding its wellness portfolio, including additional expansion into transportation hubs and launching TreatStudios.

Industry Context

XWELL's expansion into transportation hubs and focus on wellness services aligns with the growing trend of health and wellness offerings in travel and retail spaces. The company's biosurveillance program also positions it within the growing healthcare and public health sector.

Comparison to Industry Standards

• XWELL's 39% revenue growth in its XpresSpa segment is a strong performance compared to some other airport retail and service providers, although direct comparisons are difficult due to the unique nature of its wellness offerings.
• The company's cost reduction efforts, with a 40% decrease in cost of sales and a 33% decrease in administrative expenses, are significant and demonstrate a focus on operational efficiency, which is a key metric for companies in the retail and service industries.
• The expansion of the biosurveillance program with the CDC and Ginkgo Bioworks is a unique offering that sets XWELL apart from traditional wellness and retail companies, positioning it in the growing health and biosurveillance sector.
• The company's move to expand beyond airports into train stations and other venues is a strategic move to diversify its revenue streams and tap into new markets, similar to other companies that are expanding their retail and service offerings into non-traditional locations.
• The restatement of Q3 2023 financials is a negative event that could raise concerns among investors, as it indicates potential issues with the company's accounting practices. This is a concern as other companies in the sector have been under scrutiny for accounting practices.

Stakeholder Impact

• Shareholders may be concerned about the net loss and restatement of financials, but encouraged by the cost reductions and growth in the XpresSpa segment.
• Employees may be impacted by the cost reduction measures, but also benefit from the company's expansion and growth.
• Customers will benefit from the expansion of wellness services and new locations.
• Suppliers may see increased business opportunities as the company expands its operations.
• Creditors may be concerned about the company's losses, but reassured by its liquidity position.

Next Steps

• XWELL plans to continue expanding its XpresSpa and Naples Wax Center locations.
• The company intends to launch TreatStudios, a new platform for independent wellness providers.
• XWELL will continue to focus on improving operating performance and reaching profitability.
• The company will continue to expand its biosurveillance program with the CDC and Ginkgo Bioworks.

Key Dates

Keywords

XWELL, XpresSpa, Naples Wax Center, Biosurveillance, Ginkgo Bioworks, CDC, Financial Results, Cost Reduction, Revenue Growth, Operating Loss, Impairment, Wellness, Airports, Travel, Healthcare